Combination treatment for advanced solid tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called TLN-499 combined with another drug (venetoclax) for people with certain advanced solid tumors that have not responded well to previous treatments. The goal is to see if the combination is safe and might help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these cancers: small cell lung cancer, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma.
- Your cancer must have come back or not responded to earlier treatments.
- You need to have tumors that can be measured on scans.
- You should be in fairly good health (able to do light activities) and have adequate organ function.
- You must not have active brain metastases or have had major surgery in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
This study tests a new combination of two investigational drugs for people with advanced solid tumors, especially lung cancers. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new combination of drugs for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and improve outcomes.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.